Oral neflamapimod has the potential to reverse
synaptic dysfunction, improve neuron health and slow or prevent
disease progression, which would make it the first
disease-modifying treatment in DLB
Phase 2b
RewinD-LB study underway; completion of enrollment planned in 1H
2024, and topline primary efficacy results in expected in 2H
2024
BOSTON, Oct. 18,
2023 /PRNewswire/ -- CervoMed Inc. (NASDAQ: CRVO), a
clinical-stage company focused on developing treatments for
degenerative diseases of the brain, today announced it will present
deeper insights highlighting the neflamapimod clinical development
program, including findings in phase2a that led to the final Phase
2b study design for the treatment of
patients with dementia with Lewy bodies (DLB), in an oral
presentation at the 16th Clinical Trials in Alzheimer's
Disease (CTAD) conference, being held October 24-27, 2023, in Boston, Massachusetts.
"We are pleased to have the opportunity to comprehensively
present the findings in phase 2a and discuss the analyses that went
into optimizing the Phase 2b study
design for the treatment of patients with DLB at the upcoming CTAD
conference," said John Alam, MD,
Chief Executive Officer of CervoMed. "The presentation will focus
on the components of the RewinD-LB study that are intended to
increase the probability of success in this trial as we hope to
bring a new medicine to patients suffering from neurodegenerative
diseases with a high-unmet need."
Details for the CTAD 2023 Oral Presentation
Title: A Phase 2b Clinical
Trial of Neflamapimod in Dementia with Lewy Bodies Designed to
Confirm the Efficacy Results from Phase 2a
Date / Time: Wednesday, October 25,
2023 / 2:50 p.m. ET
Presenter: Niels Prins, MD,
PhD, Chief Executive Officer of Brain Research Center -
Amsterdam
Session Title: OC8 - ORAL COMMUNICATIONS
About CervoMed
CervoMed Inc. (the "Company") is a clinical-stage biotechnology
company advancing CNS-focused therapeutics to benefit patients with
a range of degenerative diseases of the brain. The Company is
currently developing neflamapimod, an investigational orally
administered small molecule brain penetrant that inhibits p38MAP
kinase alpha (p38a). Neflamapimod has the potential to treat
synaptic dysfunction, the reversible aspect of the underlying
neurodegenerative processes that cause disease in dementia with
Lewy bodies (DLB) and certain other major neurological disorders.
Neflamapimod is currently being evaluated in a Phase 2b study in patients with DLB. CervoMed was
formed in August 2023 with completion
of the merger of EIP Pharma Inc. with Diffusion
Pharmaceuticals. EIP Pharma, Inc. continues to operate as a
wholly owned subsidiary of CervoMed.
For more information, please visit www.cervomed.com or engage
with us on Twitter and LinkedIn.
Forward-Looking Statements
This press release includes express and implied forward-looking
statements within the meaning of the Private Securities Litigation
Reform Act of 1995, as amended, regarding the intentions, plans,
beliefs, expectations or forecasts for the future of the Company,
including the therapeutic potential of neflamapimod and the
anticipated timing of clinical milestones. Terms such as
"believes," "estimates," "anticipates," "expects," "plans,"
"intends," "may," "could," "might," "will," "should,"
"approximately," "potential" or other words that convey uncertainty
of future events or outcomes may identify these forward-looking
statements. Although there is believed to be reasonable basis for
each forward-looking statement contained herein, forward-looking
statements by their nature involve risks and uncertainties, known
and unknown, many of which are beyond the Company's control and, as
a result, actual results could differ materially from those
expressed or implied in any forward-looking statement. Particular
risks and uncertainties include, among other things, those related
to: the Company's available cash resources and the availability of
additional funds on acceptable terms; the likelihood and timing of
any regulatory approval of neflamapimod or the nature of any
feedback the Company may receive from the U.S. Food and Drug
Administration; and the other factors discussed under the heading
"Risk Factors" in Exhibit 99.2 to the Company's Current Report on
Form 8-K/A filed with the U.S. Securities and Exchange Commission
(SEC) on September 29, 2023, and
other filings that the Company may file from time to time with the
SEC. Any forward-looking statements in this press release speak
only as of the date hereof and the Company does not undertake
any obligation to update such forward-looking statements to reflect
events or circumstances after the date of this press release,
except to the extent required by law.
View original content to download
multimedia:https://www.prnewswire.com/news-releases/cervomed-announces-oral-presentation-at-ctad-2023-highlighting-phase-2b-neflamapimod-program-for-the-treatment-of-patients-with-dementia-with-lewy-bodies-301959620.html
SOURCE CervoMed Inc.
